Age at menopause, reproductive history, and venous thromboembolism risk among postmenopausal women: The Women's Health Initiative hormone therapy clinical trials

Menopause

Volumn 21, Issue 3, 2014, Pages 214-220

  Canonico, Marianne ^a   Plu Bureau, Geneviève ^a,b   O'Sullivan, Mary Jo ^c   Stefanick, Marcia L ^d   Cochrane, Barbara ^e   Scarabin, Pierre Yves ^a   Manson, Joann E ^f  

^a CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^b UMRS 1018 ^*  (France)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Age at menopause; Risk factors; Venous thromboembolism

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; EARLY MENOPAUSE; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; MENARCHE; MENOPAUSE; MIDDLE AGED; PARITY; PATIENT HISTORY OF BILATERAL OVARIECTOMY; PATIENT PREFERENCE; POSTMENOPAUSE; REPRODUCTIVE HEALTH; REPRODUCTIVE HISTORY; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM; WOMEN'S HEALTH;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CHILD; CLINICAL TRIALS AS TOPIC; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENARCHE; MENOPAUSE; MIDDLE AGED; OVARIECTOMY; PARITY; POSTMENOPAUSE; PREGNANCY; REPRODUCTIVE HISTORY; RISK FACTORS; VENOUS THROMBOEMBOLISM; WOMEN'S HEALTH;

EID: 84896739853     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0b013e31829752e0     Document Type: Article

References (58)

1. The greatest threat to women's health. Lancet 2003;362:1165.
2. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
3. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291: 1701-1712.
4. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 2000;83: 657-660.
5. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933-938.
6. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008;336:1227-1231.
7. Olie V, Canonico M, Scarabin PY. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr Opin Hematol 2010;17:457-463.
8. Manzoli L, De Vito C, Marzuillo C, Boccia A, Villari P. Oral contraceptives and venous thromboembolism: a systematic review and metaanalysis. Drug Saf 2012;35:191-205.
9. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-432.
10. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840-845.
11. Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010;30:340-345.
12. Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost 2010;8:979-986.
13. Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause 2011;18:1052-1059.
14. Sweetland S, Beral V, Balkwill A, et al. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost 2012;10:2277-2286.
15. Lidegaard O, Nielsen LH, Skovlund CW, Skjeldestad FE, Lokkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011;343:d6423.
16. Smith NL, Heckbert SR, Lemaitre RN, et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 2004;292:1581-1587.
17. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011;342:d2151.
18. Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011;342:d2139.
19. van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD. Age at menopause as a risk factor for cardiovascular mortality. Lancet 1996;347:714-718.
20. Hu FB, Grodstein F, Hennekens CH, et al. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med 1999;159: 1061-1066.
21. de Kleijn MJ, van der Schouw YT, Verbeek AL, Peeters PH, Banga JD, van der Graaf Y. Endogenous estrogen exposure and cardiovascular mortality risk in postmenopausal women. Am J Epidemiol 2002;155: 339-345.
22. Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006;13:265-279.
23. Lakshman R, Forouhi NG, Sharp SJ, et al. Early age at menarche associated with cardiovascular disease and mortality. J Clin Endocrinol Metab 2009;94:4953-4960.
24. Rocca WA, Grossardt BR, Miller VM, Shuster LT, Brown RD Jr. Premature menopause or early menopause and risk of ischemic stroke. Menopause 2012;19:272-277.
25. Wellons M, Ouyang P, Schreiner PJ, Herrington DM, Vaidya D. Early menopause predicts future coronary heart disease and stroke: the Multi- Ethnic Study of Atherosclerosis. Menopause 2012;19:1081-1087.
26. Monninkhof EM, van der Schouw YT, Peeters PH. Early age at menopause and breast cancer: are leaner women more protected? A prospective analysis of the Dutch DOM cohort. Breast Cancer Res Treat 1999;55: 285-291.
27. van Wayenburg CA, van der Schouw YT, van Noord PA, Peeters PH. Age at menopause, body mass index, and the risk of colorectal cancer mortality in the Dutch Diagnostisch Onderzoek Mammacarcinoom (DOM) cohort. Epidemiology 2000;11:304-308.
28. Chang CC, Chiu HF, Yang CY. Parity, age at first birth, and risk of death from pancreatic cancer: evidence from a cohort in Taiwan. Pancreas 2010;39:567-571.
29. Jansen SC, Temme EH, Schouten EG. Lifetime estrogen exposure versus age at menopause as mortality predictor. Maturitas 2002;43:105-112.
30. Jacobsen BK, Heuch I, Kvale G. Age at natural menopause and all-cause mortality: a 37-year follow-up of 19,731 Norwegian women. Am J Epidemiol 2003;157:923-929.
31. Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA. Premature menopause or early menopause: long-term health consequences. Maturitas 2010;65:161-166.
32. Coppus AM, Evenhuis HM, Verberne GJ, et al. Early age at menopause is associated with increased risk of dementia and mortality in women with Down syndrome. J Alzheimers Dis 2010;19:545-550.
33. Jacobsen BK, Knutsen SF, Oda K, Fraser GE. Parity and total, ischemic heart disease and stroke mortality. The Adventist Health Study, 1976- 1988. Eur J Epidemiol 2011;26:711-718.
34. Tamakoshi K, Yatsuya H, Tamakoshi A. Early age at menarche associated with increased all-cause mortality. Eur J Epidemiol 2011;26: 771-778.
35. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000;132: 689-696.
36. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000;160:3415-3420.
37. Simon T, Beau Yon de Jonage-Canonico M, Oger E, et al. Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism. J Thromb Haemost 2006;4:71-76.
38. Lutsey PL, Virnig BA, Durham SB, et al. Correlates and consequences of venous thromboembolism: the Iowa Women's Health Study. Am J Public Health 2010;100:1506-1513.
39. Ohira T, Folsom AR, Cushman M, et al. Reproductive history, hormone replacement, and incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology. Br J Haematol 2010; 149:606-612.
40. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials 1998;19:61-109.
41. McTiernan A, Kooperberg C, White E, et al. Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort Study. JAMA 2003;290:1331-1336.
42. Archer DF. Premature menopause increases cardiovascular risk. Climacteric 2009;12(Suppl 1):26-31.
43. Palmer JR, Rosenberg L, Shapiro S. Reproductive factors and risk of myocardial infarction. Am J Epidemiol 1992;136:408-416.
44. Ness RB, Harris T, Cobb J, et al. Number of pregnancies and the subsequent risk of cardiovascular disease. N Engl J Med 1993;328:1528-1533.
45. Qureshi AI, Giles WH, Croft JB, Stern BJ. Number of pregnancies and risk for stroke and stroke subtypes. Arch Neurol 1997;54:203-206.
46. Jacobs MB, Kritz-Silverstein D, Wingard DL, Barrett-Connor E. The association of reproductive history with all-cause and cardiovascular mortality in older women: the Rancho Bernardo Study. Fertil Steril 2012; 97:118-124.
47. de Lecinana MA, Egido JA, Fernandez C, et al. Risk of ischemic stroke and lifetime estrogen exposure. Neurology 2007;68:33-38.
48. Cui R, Iso H, Toyoshima H, et al. Relationships of age at menarche and menopause, and reproductive year with mortality from cardiovascular disease in Japanese postmenopausal women: the JACC study. J Epidemiol 2006;16:177-184.
49. Chang HS, Odongua N, Ohrr H, Sull JW, Nam CM. Reproductive risk factors for cardiovascular disease mortality among postmenopausal women in Korea: the Kangwha Cohort Study, 1985-2005. Menopause 2011;18:1205-1212.
50. Perez Gutthann S, Garcia Rodriguez LA, Castellsague J, Duque Oliart A. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 1997;314:796-800.
51. He L, Tang X, Li N, et al. Menopause with cardiovascular disease and its risk factors among rural Chinese women in Beijing: a population-based study. Maturitas 2012;72:132-138.
52. Agrinier N, Cournot M, Dallongeville J, et al. Menopause and modifiable coronary heart disease risk factors: a population based study. Maturitas 2010;65:237-243.
53. Baer HJ, Glynn RJ, Hu FB, et al. Risk factors for mortality in the Nurses' Health Study: a competing risks analysis. Am J Epidemiol 2011; 173:319-329.
54. Rossouw JE, Prentice RL, Manson, JE et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477.
55. Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-1580.
56. Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006;166: 772-780.
57. Virchow R. Phlogose und Thrombose in GefäQsystem. Gesammelte Abhandlungen zur Wissenschaftlichem Medizin. Frankfurt, Germany: Staatsdruckerei, 1856.
58. Perrot-Applanat M, Cohen-Solal K, Milgrom E, Finet M. Progesterone receptor expression in human saphenous veins. Circulation 1995;92: 2975-2983.